摘要
目的:通过比较托吡酯和硫必利治疗儿童多发性抽动症(TS)的临床疗效及安全性,为治疗儿童多发性抽动症提供理论依据。方法:选取我院60例符合DSM-l V-r IR诊断标准的儿童多发性抽动症患者,采用随机数表法分为试验组32例和对照组28例。试验组应用托吡酯治疗,每天2~3 mg/kg;对照组应用硫必利治疗,2次/天,每次50~150 mg,以抽动发作减少次数为标准评定临床疗效及安全性,并比较分析两组不良反应发生率。结果:试验组有效率为84.4%,对照组有效率为82.1%,差异无统计学意义(P>0.05)。试验组总的不良反应发生率为28.1%,对照组为46.4%,差异有统计学意义(P<0.05)。结论:托吡酯与硫必利治疗儿童多发性抽动症同样有效,但托吡酯具有更高的安全性。
Objective： Through the comparative analysis of topiramate and tiapride in treating children with Tourette syndrome（TS）,to provide theoretical basis for children with Tourette syndrome. Methods： Sixty children with Tourette syndrome who accorded with DSM-l V-r IR diagnostic criteria in the First People＇s Hospital of Wujiang District,Suzhou,were selected. All children were divided into the experimental group and the control group,the experimental group was given the topiramate treatment,2 to 3 mg/kg every day,the control group was given tiapride 50 to 150 mg every day,2 times one day. Clinical efficacy,safety and the incidence of adverse reactions were compared in two groups. Results： The efficiency of experimental group and control group were 84. 4%,82. 1%,the difference was not statistically significant（P〉0. 05）. The incidence of adverse reactions in experimental group and control group were 28. 1% and46. 4%,the difference was statistically significant（P〈0. 05）. Conclusion： Topiramate and tiapride in treating children with Tourette syndrome are equally effective,but topiramate has higher security.
出处
《儿科药学杂志》
CAS
2017年第4期20-22,共3页
Journal of Pediatric Pharmacy
